PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy.

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Trials

Background:

• Progressive supranuclear palsy (PSP) is a neurodegenerative tauopathy with limited pharmacological treatment options.
• Rasagiline, a monoamine oxidase B (MAO-B) inhibitor, exhibits neuroprotective properties in preclinical models.

Purpose of the Study:

• To assess the safety, tolerability, and therapeutic efficacy of rasagiline in mitigating symptom progression in patients with PSP.
• To determine if rasagiline impacts the rate of decline in PSP patients over a 1-year period.

Main Methods:

• A 1-year, randomized, double-blind, placebo-controlled trial involving 44 patients diagnosed with PSP.
• Primary endpoint: combined measure of symptom progression (PSP Rating Scale) and need for L-dopa medication; secondary endpoints included various functional, cognitive, and motor assessments.

Main Results:

• Rasagiline was well-tolerated, with minor increases in known side effects like hallucinations and ventricular extrasystoles.
• No statistically significant difference was observed in the primary endpoint (PSP symptom progression) between the rasagiline and placebo groups (p=0.496).
• Secondary outcome measures, including activities of daily living, depression, cognitive function, and postural stability, also showed no significant differences.

Conclusions:

• While rasagiline demonstrates good tolerability in PSP patients, it did not show a significant beneficial effect on overall symptom progression in this trial.
• Post hoc analysis suggests potential benefits in specific domains (limb motor) and possible detriments in others (mentation, history), warranting further investigation with refined endpoints.